Rising competitive pressure is hurting sales of relatively newer drugs like Zostavax and Zepatier. Zepatier sales are going down sharply due to reduction in patient volume as a result of increasing competition. Zostavax sales are expected to be hurt by strong competition from Glaxo's GSK newly approved shingles vaccines, Shingrix. Among the older products, while continued pricing pressure is hurting sales of the diabetes franchise (Januvia/Janumet), lower demand in the United States and competitive pricing pressure in Europe is hurting sales of Isentress. Remicade sales are expected to decline due to biosimilar competition in EU. Merck markets Remicade in partnership with J&J JNJ.